Background And Purpose: Resource-limited countries face challenges in setting up effective pharmacovigilance systems. This study aimed to monitor the occurrence of adverse events (AEs) after the use of artemisinin-based combination therapies (ACTs), identify potential drivers of reporting suspected adverse drug reactions (ADRs) and monitor AEs among women who were inadvertently exposed to ACTs in the first trimester of pregnancy.

Patients And Methods: We conducted a prospective observational study from May 2010 to July 2012 in Nanoro Health and Demographic Surveillance System (HDSS), Burkina Faso. The HDSS area was divided into active and passive surveillance areas to monitor AEs among patients (regardless of age or sex) who received a first-line ACT (artemether-lumefantrine or artesunate-amodiaquine). In the active surveillance area, patients were followed up for 28 days, while in the passive surveillance area, patients were encouraged to return voluntarily to the health facility to report any occurrence of AEs until day 28 after drug intake. We assessed the crude incidence rates of AEs in both cohorts and performed Cox regression with mixed random effects to identify potential drivers of ADR occurrence.

Results: In total, 3170 participants were included in the study. Of these, 40.3% had reported at least one AE, with 39.6% and 44.4% from active and passive surveillance groups, respectively. The types of ADRs were similar in both groups. The most frequent reported ADRs were anorexia, weakness, cough, dizziness and pruritus. One case of abortion and eight cases of death were reported, but none of them was related to the ACT. The variance in random factors showed a high variability of ADR occurrence between patients in both groups, whereas variability between health facilities was low in the active surveillance group and high in passive surveillance group. Taking more than two concomitant medications was associated with high hazard in ADR occurrence, whereas the rainy season was associated with low hazard.

Conclusion: This study showed that both passive and active surveillance approaches were useful tools. The HDSS allowed us to capture a few cases of exposure during the first trimester of pregnancy. The passive surveillance approach, which is more likely to be implemented by malaria control programs, seems to be more relevant in the Sub-Saharan African context.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174163PMC
http://dx.doi.org/10.2147/DDDT.S224857DOI Listing

Publication Analysis

Top Keywords

artemisinin-based combination
8
combination therapies
8
nanoro health
8
health demographic
8
demographic surveillance
8
surveillance system
8
burkina faso
8
identify potential
8
potential drivers
8
monitor aes
8

Similar Publications

Background: Triple artemisinin-based combination therapies (TACTs) can delay the spread of antimalarial drug resistance. Artesunate-amodiaquine is widely used for uncomplicated Plasmodium falciparum malaria. We therefore aimed to determine the safety and efficacy of artemether-lumefantrine-amodiaquine and artesunate-amodiaquine with and without single low-dose primaquine for reducing gametocyte carriage and transmission to mosquitoes.

View Article and Find Full Text PDF

Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance. We compared the efficacy and safety of praziquantel combined with four different artemisinin-based combinations to praziquantel alone in treating infection in Kenyan children. In this randomized, open-label, five-arm, head-to-head, non-inferiority trial, children (aged 9-15 years) with infection according to duplicate Kato Katz thick smears from a stool sample in the Mwea irrigation scheme of central Kenya, were enrolled.

View Article and Find Full Text PDF

Background: Piperaquine, used in combination with dihydroartemisinin, has been identified as a promising partner drug for uncomplicated treatment and chemoprevention of Plasmodium falciparum malaria in Africa. In light of the earlier spread of piperaquine resistance in Southeast Asia, mediated primarily by mutations in the drug efflux transporter PfCRT, we have explored whether PfCRT mutations would represent a probable path to piperaquine resistance becoming established in Africa.

Methods: We edited PfCRT mutations known to mediate piperaquine resistance in Southeast Asia into P.

View Article and Find Full Text PDF
Article Synopsis
  • - Malaria is a leading cause of mortality, particularly among children in sub-Saharan Africa, and this study aimed to examine the characteristics and treatment outcomes of malaria in children at a hospital in Gabon.
  • - Conducted from February to May 2023, the study included 306 febrile children, revealing a malaria prevalence of 17.3%, with common symptoms including high fever, chills, and nausea.
  • - Findings indicated significant issues with self-medication and non-compliance to preventive measures, complicating treatment efforts, often requiring intravenous care for severe cases.
View Article and Find Full Text PDF
Article Synopsis
  • * The primary current treatment is artemisinin-based combination therapies (ACTs), but rising resistance to these drugs, particularly in Southeast Asia, threatens advancements made in battling the disease.
  • * The review explores various antimalarial drugs, challenges of drug resistance, and the importance of new therapies and vaccines in the ongoing fight against malaria and aims for its eventual eradication.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!